Quality control methods for automated cell processing

1. A method for assessing and optimizing cellular quality of a cell-based therapy, comprising:

(a) determining one or more molecular characteristics of a pre-modified cell culture;

(b) genetically modifying the cell culture via an automated cell engineering system;

(c) automatically determining via the automated cell engineering system the one or more molecular characteristics of the modified cell culture during and after the genetically modifying; and

(d) automatically optimizing one or more parameters of the automated cell engineering system based on the automatically determined one or more molecular characteristics, by increasing or decreasing a flow rate of cell media, increasing or decreasing oxygen concentration, increasing or decreasing carbon dioxide concentration, increasing or decreasing a glucose level, increasing or decreasing a pH of cell media, and/or modifying a selection reagent used in a cell isolation procedure, to alter the one or more molecular characteristics of the modified cell culture.

2. The method of claim 1 , wherein the one or more molecular characteristics are selected from the group consisting of a gene expression, a protein expression, an mRNA expression, and a copy number variation.

3. The method of claim 1 , wherein the cell culture is selected from the group consisting of an immune cell culture, a natural killer cell culture, and a stem cell.

4. The method of claim 3 , wherein the immune cell culture is a chimeric antigen receptor T (CAR T) cell culture.

5. The method of claim 4 , wherein the one or more molecular characteristics include T-cell activation, metabolism, exhaustion, and T-cell receptor diversity.

6. The method of claim 1 , further comprising automatically optimizing one or more parameters of the automated cell engineering system based on the determined one or more molecular characteristics of step (a) by modifying a selection of a cell transduction procedure and/or modifying a selection of a vector for use in a transduction procedure.

7. A method for assessing and optimizing cellular quality of a cell-based therapy, comprising:

(a) determining one or more molecular characteristics of a pre-modified cell culture;

(b) optimizing one or more parameters of an automated cell engineering systems to alter one the one or more molecular characteristics of the pre-modified cell culture;

(c) activating the pre-modified cell culture with an activation reagent to produce an activated cell culture;

(d) transducing the activated cell culture with a vector, to produce a transduced cell culture;

(e) expanding the transduced cell culture;

(f) concentrating the expanded cell culture of (e);

(g) harvesting the concentrated cell culture of (f) to produce a genetically modified cell culture;

(h) automatically determining via the automated cell engineering system the one or more molecular characteristics of the cell culture selected from the group consisting of a gene expression, a protein expression, an mRNA expression, and a copy number variation during or after any one of steps (c)-(g); and

(i) automatically optimizing one or more parameters based on the automatically determined one or more molecular characteristics of the cell culture, by increasing or decreasing a flow rate of cell media, increasing or decreasing oxygen concentration, increasing or decreasing carbon dioxide concentration, increasing or decreasing a glucose level, increasing or decreasing a pH of cell media, and/or modifying a selection reagent used in a cell isolation procedure to alter the one or more molecular characteristics of the cell culture.

8. The method of claim 7 , wherein the cell culture is selected from the group consisting of an immune cell culture, a natural killer cell culture, and a stem cell.

9. The method of claim 8 , wherein the immune cell culture is a chimeric antigen receptor T (CAR T) cell culture.

10. The method of claim 9 , wherein the one or more molecular characteristics include T-cell activation, metabolism, exhaustion, and T-cell receptor diversity.

11. A method for assessing and optimizing cellular quality of a chimeric antigen receptor T (CAR T) cell culture, comprising:

(a) determining one or more molecular characteristics of a pre-modified T-cell culture;

(b) optimizing one or more parameters of an automated cell engineering system to alter the one or more molecular characteristics of the pre-modified T-cell culture;

(c) activating the pre-modified T-cell culture with an activation reagent to produce an activated T-cell culture;

(d) transducing the activated T-cell culture with a vector encoding a chimeric antigen receptor, to produce a CAR T-cell culture;

(e) expanding the CAR T-cell culture;

(f) concentrating the expanded CAR T-cell culture of (e);

(g) harvesting the concentrated CAR-T cell culture of (f);

(h) automatically determining via the automated cell engineering system the one or more molecular characteristics of the CAR T-cell culture during or after any one of steps (c)-(g); and

(i) automatically optimizing one or more parameters of any one of steps (c)-(g) to alter the one or more molecular characteristics of the CAR T-cell culture based on the automatically determined one or more molecular characteristics, wherein the optimizing includes one or more of increasing or decreasing a flow rate of cell media, increasing or decreasing oxygen concentration, increasing or decreasing carbon dioxide concentration, increasing or decreasing a glucose level, increasing or decreasing a pH of cell media, and/or modifying a selection reagent used in a cell isolation procedure.

12. The method of claim 11 , wherein the method produces about 100 million viable CAR T-cells.

13. The method of claim 11 , wherein the T-cell culture comprises at least one accessory cell, peripheral blood mononuclear cells and/or purified T-cells.

14. The method of claim 13 , wherein the accessory cell comprises a monocyte or a monocyte-derived cell and antigens for a T-cell receptor comprising CD28, CD40, CD2, CD40L and/or ICOS.

15. The method of claim 11 , wherein the activation reagent comprises an antibody or a dendritic cell.

16. The method of claim 15 , wherein the antibody is a soluble antibody, comprises at least one of an anti-CD3 antibody and an anti-CD28 antibody and/or is immobilized on a surface.

17. The method of claim 16 , wherein the surface is a surface of a bead.

18. The method of claim 11 , wherein the transducing comprises viral infection, electroporation, membrane disruption, or combinations thereof.

19. The method of claim 11 , wherein the vector is a lentiviral vector or a retrovirus.

20. The method of claim 11 , wherein the one or more molecular characteristics of the pre-modified T-cell culture include T-cell activation, metabolism, exhaustion, and T-cell receptor diversity, and wherein the one or more molecular characteristics of the CAR T-cell culture during or after any one of steps (c)-(g) are selected from the group consisting of a gene expression, a protein expression, an mRNA expression, and a copy number variation.

21. The method of claim 11 , wherein at least 500 gene expressions are determined.

22. The method of claim 11 , wherein the optimizing further includes increasing or decreasing a temperature of the CAR T-cell culture.

23. A method for assessing and optimizing cellular quality of a cell culture, comprising:

(a) determining one or more molecular characteristics of a pre-modified cell culture;

(b) genetically modifying the cell culture via an automated cell engineering system;

(c) automatically determining via the automated cell engineering system the one or more molecular characteristics of the modified cell culture during and after the genetically modifying; and

(d) automatically optimizing one or more parameters of the automated cell engineering system based on the automatically determined one or more molecular characteristics to alter the one or more molecular characteristics of the modified cell culture, wherein the optimizing includes one or more of increasing or decreasing a flow rate of cell media, increasing or decreasing oxygen concentration, increasing or decreasing carbon dioxide concentration, increasing or decrease a glucose level, increasing or decreasing a pH of cell media, and/or modifying a selection reagent used in a cell isolation procedure.